Abstract
Recent studies across multiple tumour types are starting to reveal a recurrent regulatory architecture in which genomic alterations cluster upstream of functional master regulator (MR) proteins, the aberrant activity of which is both necessary and sufficient to maintain tumour cell state. These proteins form small, hyperconnected and autoregulated modules (termed tumour checkpoints) that are increasingly emerging as optimal biomarkers and therapeutic targets. Crucially, as their activity is mostly dysregulated in a post-translational manner, rather than by mutations in their corresponding genes or by differential expression, the identification of MR proteins by conventional methods is challenging. In this Opinion article, we discuss novel methods for the systematic analysis of MR proteins and of the modular regulatory architecture they implement, including their use as a valuable reductionist framework to study the genetic heterogeneity of human disease and to drive key translational applications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014).
Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).
Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Oakman, C., Santarpia, L. & Di Leo, A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 7, 725–732 (2010).
Chen, J. C. et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 159, 402–414 (2014).
Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).
Aytes, A. et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638–651 (2014).
Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318–325 (2010).
Bisikirska, B. et al. Elucidation and pharmacological targeting of novel molecular drivers of follicular lymphoma progression. Cancer Res. 76, 664–674 (2016).
Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939 (2004).
Nambu, J. R., Lewis, J. O., Wharton, K. A. Jr & Crews, S. T. The Drosophila single-minded gene encodes a helix–loop–helix protein that acts as a master regulator of CNS midline development. Cell 67, 1157–1167 (1991).
Resnick, M. A., Tomso, D., Inga, A., Menendez, D. & Bell, D. Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle 4, 1026–1029 (2005).
Klapper, L. N., Kirschbaum, M. H., Sela, M. & Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25–79 (2000).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Dalla-Favera, R. et al. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl Acad. Sci. USA 79, 7824–7827 (1982).
Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl Acad. Sci. USA 100, 2639–2644 (2003).
Akavia, U. D. et al. An integrated approach to uncover drivers of cancer. Cell 143, 1005–1017 (2010).
Gu, J. et al. Gene module based regulator inference identifying miR-139 as a tumor suppressor in colorectal cancer. Mol. Biosyst. 10, 3249–3254 (2014).
Ergun, A., Lawrence, C. A., Kohanski, M. A., Brennan, T. A. & Collins, J. J. A network biology approach to prostate cancer. Mol. Syst. Biol. 3, 82 (2007).
Cannon, W. B. Organization for physiological homeostasis. Physiol. Rev. 9, 399–431 (1929).
Waddington, C. H. Canalization of development and genetic assimilation of acquired characters. Nature 183, 1654–1655 (1959).
Waddington, C. H. Genetic assimilation. Adv. Genet. 10, 257–293 (1961).
Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3, 807–821 (2003).
Carter, S. B. Tissue homeostasis and the biological basis of cancer. Nature 220, 970–974 (1968).
Young, S. R. et al. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate 73, 1251–1262 (2013).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
Rodriguez-Barrueco, R. et al. Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+ breast cancers. Genes Dev. 29, 1631–1648 (2015).
Piovan, E. et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 24, 766–776 (2013).
Mitrofanova, A., Aytes, A., Shen, C., Abate-Shen, C. & Califano, A. A systems biology approach to predict drug response for human prostate cancer based on in vivo preclinical analyses of mouse models. Cell Rep. 12, 1–12 (2015).
Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861–1874 (2001).
Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115–119 (2011).
Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).
Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
Wayne, D. W. Kolmogorov–Smirnov One-sample Test: Applied Nonparametric Statistics 2nd edn 319–330 (PWS-Kent, 1990).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838–847 (2016).
Lefebvre, C. et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377 (2010).
Castro, M. A. et al. Regulators of genetic risk of breast cancer identified by integrative network analysis. Nat. Genet. 48, 12–21 (2016).
Zhang, S. et al. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci. Rep. 5, 16066 (2015).
Yepes, S., Torres, M. M. & Lopez-Kleine, L. Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia. BMC Genomics 16, 1002 (2015).
Remo, A. et al. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. J. Transl Med. 13, 138 (2015).
Fletcher, M. N. et al. Master regulators of FGFR2 signalling and breast cancer risk. Nat. Commun. 4, 2464 (2013).
Tanaka, H. & Ogishima, S. Network biology approach to epithelial-mesenchymal transition in cancer metastasis: three stage theory. J. Mol. Cell Biol. 7, 253–266 (2015).
Piao, G. et al. A computational procedure for identifying master regulator candidates: a case study on diabetes progression in Goto–Kakizaki rats. BMC Syst. Biol. 6 (Suppl. 1), S2 (2012).
Liang, Y. et al. Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J. Biol. Chem. 287, 33533–33544 (2012).
Califano, A., Butte, A. J., Friend, S., Ideker, T. & Schadt, E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 44, 841–847 (2012).
Pe'er, D. & Hacohen, N. Principles and strategies for developing network models in cancer. Cell 144, 864–873 (2011).
Tovar, H., Garcia-Herrera, R., Espinal-Enriquez, J. & Hernandez-Lemus, E. Transcriptional master regulator analysis in breast cancer genetic networks. Comput. Biol. Chem. 59B, 67–77 (2015).
Sartor, I. T., Zeidan-Chulia, F., Albanus, R. D., Dalmolin, R. J. & Moreira, J. C. Computational analyses reveal a prognostic impact of TULP3 as a transcriptional master regulator in pancreatic ductal adenocarcinoma. Mol. Biosyst. 10, 1461–1468 (2014).
Lim, W. K., Lyashenko, E. & Califano, A. Master regulators used as breast cancer metastasis classifiers. Pac. Symp. Biocomput. 14, 504–515 (2009).
Ikiz, B. et al. Dissecting the regulatory machinery of neurodegeneration in an in vitro model of amyotrophic lateral sclerosis. Cell Rep. 12, 335–345 (2015).
Aubry, S. et al. Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. PLoS ONE 10, e0120352 (2015).
Brichta, L. et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat. Neurosci. 18, 1325–1333 (2015).
Repunte-Canonigo, V. et al. Identifying candidate drivers of alcohol dependence-induced excessive drinking by assembly and interrogation of brain-specific regulatory networks. Genome Biol. 16, 68 (2015).
Kushwaha, R. et al. Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. Stem Cells 33, 367–377 (2015).
Ravasi, T. et al. An atlas of combinatorial transcriptional regulation in mouse and man. Cell 140, 744–752 (2010).
Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382–390 (2005).
ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799–816 (2007).
Sumazin, P. et al. An extensive microRNA-mediated network of RNA–RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147, 370–381 (2011).
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. Cell 115, 787–798 (2003).
Friedlander, M. R. et al. Discovering microRNAs from deep sequencing data using miRDeep. Nat. Biotechnol. 26, 407–415 (2008).
Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173–1178 (2005).
Bandyopadhyay, S. et al. A human MAP kinase interactome. Nat. Methods 7, 801–805 (2010).
Wang, K. et al. Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat. Biotechnol. 27, 829–839 (2009).
Zhang, Q. C. et al. Structure-based prediction of protein-protein interactions on a genome-wide scale. Nature 490, 556–560 (2012).
AlQuraishi, M., Koytiger, G., Jenney, A., MacBeath, G. & Sorger, P. K. A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. Nat. Genet. 46, 1363–1367 (2014).
Faith, J. J. et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 5, e8 (2007).
Friedman, N. Inferring cellular networks using probabilistic graphical models. Science 303, 799–805 (2004).
Kundaje, A. et al. Learning regulatory programs that accurately predict differential expression with MEDUSA. Ann. NY Acad. Sci. 1115, 178–202 (2007).
Kramer, A., Green, J., Pollard, J. Jr & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523–530 (2014).
Maher, B. ENCODE: the human encyclopaedia. Nature 489, 46–48 (2012).
Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261–18266 (2006).
Affara, M. et al. Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis. BMC Genomics 14, 23 (2013).
Werner, H. M., Mills, G. B. & Ram, P. T. Cancer systems biology: a peek into the future of patient care? Nat. Rev. Clin. Oncol. 11, 167–176 (2014).
Saito, M. et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 106, 11294–11299 (2009).
Luscombe, N. M. et al. Genomic analysis of regulatory network dynamics reveals large topological changes. Nature 431, 308–312 (2004).
Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173 (2006).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
Wapinski, O. L. et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 155, 621–635 (2013).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Chudnovsky, Y. et al. ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 6, 313–324 (2014).
Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
US National Library of Medicine. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02066532 (2014).
Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19, 368–371 (2013).
Woyach, J. A. et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286–2294 (2014).
Flusberg, D. A. & Sorger, P. K. Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging. Phys. Biol. 10, 035002 (2013).
Fenner, A. Prostate cancer: next-generation RNA sequencing identifies gene signature of neuroendocrine differentiation in prostate tumors. Nat. Rev. Urol. 9, 8 (2012).
Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 122, 3398–3406 (2012).
Wei, G. et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331–342 (2006).
Rubin, E. H. & Gilliland, D. G. Drug development and clinical trials—the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9, 215–222 (2012).
Shelanski, M. et al. A systems approach to drug discovery in Alzheimer's disease. Neurotherapeutics 12, 126–131 (2015).
Schadt, E. E. et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37, 710–717 (2005).
Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10, 1108–1115 (2013).
Alvarez, M. J., Chen, J. C. & Califano, A. DIGGIT: a Bioconductor package to infer genetic variants driving cellular phenotypes. Bioinformatics 31, 4032–4034 (2015).
Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297, 63–64 (2002).
Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566 (1996).
Wang, X., Haswell, J. R. & Roberts, C. W. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer—mechanisms and potential therapeutic insights. Clin. Cancer Res. 20, 21–27 (2014).
Vazquez, M., Valencia, A. & Pons, T. Structure-PPi: a module for the annotation of cancer-related single-nucleotide variants at protein-protein interfaces. Bioinformatics 31, 2397–2399 (2015).
Morris, J. P. t., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683–695 (2010).
Dhomen, N. & Marais, R. BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529–545 (2009).
Davoli, A., Hocevar, B. A. & Brown, T. L. Progression and treatment of HER2-positive breast cancer. Cancer Chemother. Pharmacol. 65, 611–623 (2010).
Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213–1222 (2014).
Woo, J. H. et al. Elucidating compound mechanism of action by network dysregulation analysis in pertubed cells. Cell 162, 441–451 (2015).
Tallarida, R. J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319, 1–7 (2006).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).
Park, H. S. & Jun, C. H. A simple and fast algorithm for K-medoids clustering. Expert Systems With Appl. 36, 3336–3341 (2009).
Lefebvre, C., Rieckhof, G. & Califano, A. Reverse-engineering human regulatory networks. Wiley Interdiscip. Rev. Syst. Biol. Med. 4, 311–325 (2012).
Linding, R. et al. Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415–1426 (2007).
Srivas, R. et al. Assembling global maps of cellular function through integrative analysis of physical and genetic networks. Nat. Protoc. 6, 1308–1323 (2011).
Rhodes, D. R. et al. Mining for regulatory programs in the cancer transcriptome. Nat. Genet. 37, 579–583 (2005).
Lachmann, A. et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438–2444 (2010).
Needham, C. J., Bradford, J. R., Bulpitt, A. J. & Westhead, D. R. Inference in Bayesian networks. Nat. Biotechnol. 24, 51–53 (2006).
Yeung, M. K., Tegner, J. & Collins, J. J. Reverse engineering gene networks using singular value decomposition and robust regression. Proc. Natl Acad. Sci. USA 99, 6163–6168 (2002).
Martinez, M. R. et al. Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis. Proc. Natl Acad. Sci. USA 109, 2672–2677 (2012).
Polynikis, A., Hogan, S. J. & di Bernardo, M. Comparing different ODE modelling approaches for gene regulatory networks. J. Theor. Biol. 261, 511–530 (2009).
Stuart, J. M., Segal, E., Koller, D. & Kim, S. K. A gene-coexpression network for global discovery of conserved genetic modules. Science 302, 249–255 (2003).
Horvath, S. & Dong, J. Geometric interpretation of gene coexpression network analysis. PLoS Comput. Biol. 4, e1000117 (2008).
Jansen, R. et al. A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science 302, 449–453 (2003).
He, F., Balling, R. & Zeng, A. P. Reverse engineering and verification of gene networks: principles, assumptions, and limitations of present methods and future perspectives. J. Biotechnol. 144, 190–203 (2009).
Stolovitzky, G., Prill, R. J. & Califano, A. Lessons from the DREAM2 Challenges. Ann. NY Acad. Sci. 1158, 159–195 (2009).
Marbach, D. et al. Revealing strengths and weaknesses of methods for gene network inference. Proc. Natl Acad. Sci. USA 107, 6286–6291 (2010).
Bussemaker, H. J., Li, H. & Siggia, E. D. Regulatory element detection using correlation with expression. Nat. Genet. 27, 167–171 (2001).
Fiedler, D. et al. Functional organization of the S. cerevisiae phosphorylation network. Cell 136, 952–963 (2009).
Mani, K. M. et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol. Syst. Biol. 4, 169 (2008).
Ideker, T. & Krogan, N. J. Differential network biology. Mol. Syst. Biol. 8, 565 (2012).
Barrios-Rodiles, M. et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307, 1621–1625 (2005).
Saez-Rodriguez, J. et al. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res. 71, 5400–5411 (2011).
Menashe, I. et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 70, 4453–4459 (2010).
Laoukili, J. et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nature Cell Biol. 7, 126–136 (2005).
Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151–1161 (2013).
Flusberg, D. A., Roux, J., Spencer, S. L. & Sorger, P. K. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol. Biol. Cell 24, 2186–2200 (2013).
Roschewski, M., Staudt, L. M. & Wilson, W. H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat. Rev. Clin. Oncol. 11, 12–23 (2014).
Acknowledgements
This work was supported by the National Cancer Institute (NCI) Cancer Target Discovery and Development Program (1U01CA168426), NCI Outstanding Investigator Award (R35CA197745) for A.C., NCI Research Centers for Cancer Systems Biology Consortium (1U54CA209997) and the NIH instrumentation grants (S10OD012351 and S10OD021764).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.C. is founder of DarwinHealth, Inc. M.J.A. has been employed by DarwinHealth, Inc. since March 2016.
Related links
Glossary
- Bayesian networks
-
Probabilistic models representing the probabilities and conditional probabilities of variables representing nodes in a directed acyclic graph, that is, a type of network with nodes connected by directionally defined edges, usually represented as arrows, with no circular paths (cycles). This model is often used to determine the probability of an unknown event corresponding to one node as a function of the probability of other known events in the network.
- Dystatic
-
Describes the aberrant processes responsible for implementing and maintaining a stable disease state, independent of most genetic, epigenetic and environmental perturbations.
- Feed-forward loops
-
Regulatory structures in which a gene product (A) regulates a second gene product (B) and, together, A and B regulate one or more target gene products. These structures constitute a directed acyclic graph.
- Homeostasis
-
The set of regulatory processes that ensures the overall stability of a system state, independent of endogenous and exogenous variables.
- Interactomes
-
Sets of molecular interactions that constitute the regulatory logic of cells representative of a specific tissue and organism.
- Isobologram
-
A two-dimensional map representing the viability of a cell following perturbation with a combination of two compounds. Each isobologram axis represents the concentration of an individual compound. This diagram is used to quantitatively assess whether the effect of the compound pair is additive, synergistic or antagonistic. This assessment is based on whether the isoboles (that is, curves in the diagram representing isopotency of the combination) are linear or nonlinear. Linear isoboles indicate additive behaviour, whereas nonlinear isoboles indicate synergistic (supra-additive) or antagonistic (sub-additive) behaviour.
- Master regulator
-
(MR). Type of protein participating in a modular regulatory structure (that is, tumour checkpoint), the aberrant activity of which is both necessary and sufficient for tumour cell state implementation and maintenance and which directly controls the transcriptional state of a tumour cell.
- Multiple hypothesis testing
-
When a test is repeated multiple times for — instance, a pair of dice are thrown multiple times — the probability of an outcome must be adjusted. This is a common problem in genetics, for example, where a large number of loci are tested to assess whether they are mutated in a cancer cohort, thus increasing the overall probability that any one of them may be mutated by chance.
- Oncogene addiction hypothesis
-
The hypothesis that tumours become dependent on the aberrant activity of proteins encoded by mutated oncogenes and that pharmacological inhibition of these proteins will cause tumour demise.
- Oncotecture
-
The regulatory architecture responsible for implementing tumour dystasis, comprising one or more tumour checkpoints that are responsible for integrating the effect of multiple mutations and aberrant signals in their upstream pathways to implement a conserved repertoire of downstream transcriptional programmes that are necessary and sufficient for tumour phenotype presentation.
- Regulatory logic
-
The full complement of transcriptional, post-transcriptional and post-translational molecular interactions that determine cell behaviour.
- Regulons
-
The full complement of transcriptional targets that are regulated by a protein. These can include either direct physical targets, for transcription factors and cofactors, or indirect targets for signal transduction.
- Reverse engineering
-
Systematic dissection of the molecular interactions that comprise the regulatory logic of the cell.
- Sample barcoding
-
A technique enabling incorporation of a predefined nucleic acid sequence (barcode) to tag either DNA or RNA molecules coming from a common sample so that they can be sequenced as a pool while retaining the ability to deconvolute which sample they came from.
- Silhouette score
-
A measure, from −1 to 1, of how similar an object is to its own cluster compared with the closest other cluster.
- Synthetic lethal
-
An interaction between two genes in which knockout of either gene in isolation has no (or minimal) negative impact on cell viability whereas knockout of both genes is lethal.
- Tissue microarrays
-
(TMAs). Paraffin blocks in which up to 1,000 separate tissue cores are embedded in a grid to support multiplexed immunohistological analyses.
- Tumour checkpoint
-
A small, autoregulated module comprising one or more master regulator (MR) proteins, the concerted activity of which is both necessary and sufficient for the implementation and maintenance of a tumour cell state.
Rights and permissions
About this article
Cite this article
Califano, A., Alvarez, M. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat Rev Cancer 17, 116–130 (2017). https://doi.org/10.1038/nrc.2016.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc.2016.124
This article is cited by
-
Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma
BMC Medical Genomics (2024)
-
Pancancer network analysis reveals key master regulators for cancer invasiveness
Journal of Translational Medicine (2023)
-
Critical transition and reversion of tumorigenesis
Experimental & Molecular Medicine (2023)
-
NetBID2 provides comprehensive hidden driver analysis
Nature Communications (2023)
-
Systematic identification of gene combinations to target in innate immune cells to enhance T cell activation
Nature Communications (2023)